Literature DB >> 15056736

Treatment of age-related macular degeneration.

Andrew C Browning1, Winfried M Amoaku, Harminda S Dua.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15056736      PMCID： PMC1079352          DOI： 10.1177/014107680409700403

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  25 in total

Review 1.  Age related macular degeneration.

Authors:  Amresh Chopdar; Usha Chakravarthy; Dinesh Verma
Journal:  BMJ       Date:  2003-03-01

2.  A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.

Authors:  Mark C Gillies; Judy M Simpson; Wei Luo; Philip Penfold; Alex B L Hunyor; William Chua; Paul Mitchell; Frank Billson
Journal:  Arch Ophthalmol       Date:  2003-05

3.  Recent advances in the treatment of exudative age-related macular degeneration, including transpupillary thermotherapy.

Authors:  Thomas A Ciulla
Journal:  Acta Ophthalmol Scand       Date:  2003-04

4.  Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up.

Authors:  Peep V Algvere; Carina Libert; Gunnar Lindgärde; Stefan Seregard
Journal:  Acta Ophthalmol Scand       Date:  2003-04

5.  Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1986-04

6.  Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration.

Authors:  Sabine Aisenbrey; Bart A Lafaut; Peter Szurman; Salvatore Grisanti; Christoph Lüke; Ralf Krott; Gabriele Thumann; Julia Fricke; Antje Neugebauer; Ralf-Dieter Hilgers; Peter Esser; Peter Walter; Karl Ulrich Bartz-Schmidt
Journal:  Arch Ophthalmol       Date:  2002-04

7.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Authors:  Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2002-03

8.  Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.

Authors: 
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

9.  Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

Authors:  Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donati; Gary Edd Fish; Laurie A Haynes; Hilel Lewis; Joan W Miller; Jordi M Monés; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenburg; Lawrence J Singerman; Jason S Slakter; Andrew Strong; Stéphane Vannier
Journal:  Arch Ophthalmol       Date:  2002-10

10.  Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.

Authors:  Donald J D'Amico; Morton F Goldberg; Henry Hudson; Janice A Jerdan; D Scott Krueger; Susan P Luna; Stella M Robertson; Stephen Russell; Lawrence Singerman; Jason S Slakter; Lawrence Yannuzzi; Patricia Zilliox
Journal:  Ophthalmology       Date:  2003-12       Impact factor: 12.079
View more
  2 in total

1.  Treatment of age-related macular degeneration.

Authors:  David L Boase
Journal:  J R Soc Med       Date:  2004-07       Impact factor: 18.000

2.  Design and development of artemisinin and dexamethasone loaded topical nanodispersion for the effective treatment of age-related macular degeneration.

Authors:  Chandrasekar Ponnusamy; Abimanyu Sugumaran; Venkateshwaran Krishnaswami; Ruckmani Kandasamy; Subramanian Natesan
Journal:  IET Nanobiotechnol       Date:  2019-10       Impact factor: 1.847
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.